Spirocyclic indolines as IL-17 modulators

Patent metadata

Field	Value
Publication number	US-11052076-B2
Application number	US-201816619573-A
Country	US
Kind code	B2
Filing date	Jun 12, 2018
Priority date	Jun 14, 2017
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

First claim

The invention claimed is:

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:

wherein
ring A represents C 3-9 cycloalkyl, C 3-7 heterocycloalkyl or C 4-9 heterobicycloalkyl, any of which groups may be optionally substituted by one or more substituents;
B represents C—R 2 or N;
D represents C—R 3 or N;
E represents C—R 4 or N;
R 0 represents hydrogen or C 1-6 alkyl;
R 1 represents —COR a ;
R a represents —CH(R 5 )N(H)C(O)R 6 , —CH(R 5 )N(H)S(O) 2 R 6 , —C(═CR 5a R 5b )N(H)C(O)R 6 , —CH(R 5 )R 7 , —CH(R 5 )N(H)R 7 or —CH(R 5 )C(O)N(H)R 7 ;
R 2 represents hydrogen, halogen, cyano, C 1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxy, C 1-6 alkoxy, difluoromethoxy, trifluoromethoxy, C 1-6 alkyl-sulphinyl or C 1-6 alkylsulphonyl;
R 3 represents hydrogen, halogen, cyano, C 1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxy, C 1-6 alkoxy, difluoromethoxy, trifluoromethoxy, C 1-6 alkyl-sulphinyl or C 1-6 alkylsulphonyl;
R 4 represents hydrogen, halogen, cyano, C 1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxy, C 1-6 alkoxy, difluoromethoxy, trifluoromethoxy, C 1-6 alkyl-sulphinyl or C 1-6 alkylsulphonyl;
R 5 represents hydrogen; or R 5 represents C 1-5 alkyl, C 3-9 cycloalkyl, C 3-9 cyclo-alkyl(C 1-5 )alkyl, C 4-9 bicycloalkyl, C 4-9 bicycloalkyl(C 1-5 )alkyl, C 5-9 spirocycloalkyl, C 5-9 spirocycloalkyl(C 1-5 )alkyl, C 9-11 tricycloalkyl, C 9-11 tricycloalkyl(C 1-5 )alkyl, aryl, aryl-(C 1-5 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-5 )alkyl, heteroaryl or heteroaryl(C 1-5 )alkyl, any of which groups may be optionally substituted by one or more substituents;
R 5a represents C 3-7 cycloalkyl, C 4-9 bicycloalkyl, aryl, C 3-7 heterocycloalkyl or heteroaryl, any of which groups may be optionally substituted by one or more substituents; and
R 5b represents hydrogen or C 1-6 alkyl; or
R 5a and R 5b , when taken together with the carbon atom to which they are both attached, represent C 3-7 cycloalkyl, C 4-9 bicycloalkyl or C 3-7 heterocycloalkyl, any of which groups may be optionally substituted by one or more substituents;
R 6 represents —NR 6a R 6b or —OR 6c ; or R 6 represents C 1-9 alkyl, C 3-9 cycloalkyl, C 3-9 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl-(C 1-6 )alkyl, heteroaryl, heteroaryl(C 1-6 )alkyl or spiro[(C 3-7 )heterocycloalkyl][heteroaryl], any of which groups may be optionally substituted by one or more substituents;
R 6a represents hydrogen; or R 6a represents C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cyclo-alkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-6 )-alkyl, heteroaryl, heteroaryl(C 1-6 )alkyl or spiro[(C 3-7 )heterocycloalkyl][heteroaryl], any of which groups may be optionally substituted by one or more substituents;
R 6b represents hydrogen or C 1-6 alkyl;
R 6c represents C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl(C 1-6 )alkyl, aryl, aryl(C 1-6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-6 )alkyl, heteroaryl or heteroaryl(C 1-6 )alkyl, any of which groups may be optionally substituted by one or more substituents; and
R 7 represents aryl, heteroaryl or spiro[(C 3-7 )heterocycloalkyl][heteroaryl], any of which groups may be optionally substituted by one or more substituents.

2. A compound as claimed in claim 1 represented by formula (I-1), (I-2), (I-3), (I-4) or (I-5), or a pharmaceutically acceptable salt thereof:

wherein A, R 0 , R 1 , R 2 , R 3 and R 4 are as defined in claim 1 .

3. A compound as claimed in claim 1 represented by formula (IIA), or a pharmaceutically acceptable salt thereof:

wherein
W represents O, S, S(O), S(O) 2 , S(O)(NH) or N—R 17 ;
R 17 represents hydrogen or C 1-6 alkyl;
R 0 , R 3 ,
R 5 and R 6 are as defined in claim 1 .

4. A compound as claimed in claim 1 represented by formula (IIB), or a pharmaceutically acceptable salt thereof:

wherein
W represents O, S, S(O), S(O) 2 , S(O)(NH) or N—R 17 ;
R 17 represents hydrogen or C 1-6 alkyl; and
R 0 , R 5 and R 6 are as defined in claim 1 .

5. A compound as claimed in claim 1 wherein R 5 represents C 1-5 alkyl, C 3-9 cycloalkyl, C 3-9 cycloalkyl(C 1-5 )alkyl, C 4-9 bicycloalkyl, C 4-9 bicycloalkyl(C 1-5 )-alkyl, C 5-9 spirocycloalkyl, C 9-11 tricycloalkyl, C 9-11 tricycloalkyl(C 1-5 )alkyl, aryl, aryl-(C 1-5 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl(C 1-5 )alkyl or heteroaryl(C 1-5 )alkyl, any of which groups may be optionally substituted by one, two or three substituents independently selected from halogen, C 1-6 alkyl, trifluoromethyl, phenyl and C 1-6 alkoxy.

6. A compound as claimed in claim 1 wherein R 6 represents —NR 6a R 6b or —OR 6c ; or R 6 represents C 1-9 alkyl, aryl, C 3-7 heterocycloalkyl, heteroaryl, heteroaryl(C 1-6 )alkyl or spiro[(C 3-7 )heterocycloalkyl][heteroaryl], any of which groups may be optionally substituted by one, two or three substituents independently selected from halogen, C 1-6 alkyl, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, trifluoropropyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, hydroxy, hydroxy(C 1-6 )alkyl, oxo, C 1-6 alkoxy(C 1-6 )alkyl, C 1-6 alkylsulfonyl, amino, amino(C 1-6 )alkyl, di(C 1-6 )alkyl-amino(C 1-6 )alkyl and tetrahydropyranyl.

7. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 , or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

8. A method for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, chronic obstructive pulmonary disease, atopic dermatitis, arthritis, rheumatoid arthritis, systemic onset juvenile idiopathic arthritis, systemic lupus erythematosus, asthma, scleroderma, systemic sclerosis, lung fibrosis, Crohn's disease, ulcerative colitis and pain, which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined in claim 1 , or a pharmaceutically acceptable salt thereof.

9. A compound as claimed in claim 1 represented by formula (IA), or a pharmaceutically acceptable salt thereof:

wherein A, B, D, E, R 0 , R 5 and R 6 are as defined in claim 1 .

10. A compound as claimed in claim 1 represented by formula (IB), or a pharmaceutically acceptable salt thereof:

wherein A, B, D, E, R 0 , R 5 and R 6 are as defined in claim 1 .

11. A compound as claimed in claim 1 represented by formula (IC), or a pharmaceutically acceptable salt thereof:

wherein A, B, D, E, R 0 , R 5 and R 7 are as defined in claim 1 .

12. A compound as claimed in claim 1 represented by formula (ID), or a pharmaceutically acceptable salt thereof:

Assignees

• UCB Biopharma SRL

Inventors

• Brace Gareth Neil
• Chappell Rose Elizabeth
• Deboves Hervé Jean Claude
• Foley Anne Marie
• Foulkes Gregory
• Jones Elizabeth Pearl
• Lecomte Fabien Claude
• Quincey Joanna Rachel
• Schulze Monika-Sarah Elisabeth Dorothea
• Selby Matthew Duncan
• Smalley Adam Peter
• Taylor Richard David
• Townsend Robert James
• Zhu Zhaoning

Classifications

• C07D495/10

  Spiro-condensed systems · CPC title

• C07D471/10

  Spiro-condensed systems · CPC title

• A61K31/4196

  1,2,4-Triazoles · CPC title

• A61K31/4155

  non condensed and containing further heterocyclic rings · CPC title

• C07D487/10

  Spiro-condensed systems · CPC title